医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PhableCare Raises INR 187 Cr (USD 25 M) in Series B Funding

2022年04月11日 PM09:38
このエントリーをはてなブックマークに追加


 

BANGALORE, India

Bengaluru headquartered PhableCare, India’s largest chronic disease management company, has raised Series B funding of INR 187 crores (USD 25 Million) within one year of raising Series A. The round was led by Kalaari Capital with participation from Aflac Ventures, Digital Horizon, Stride Ventures. Existing investors, Omron Ventures, SOSV, Social Starts, and Fresco Capital also participated in the round.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005341/en/

L-R: Sumit Sinha and Mukesh Bansal, Co-Founders, PhableCare (Photo: Business Wire)

L-R: Sumit Sinha and Mukesh Bansal, Co-Founders, PhableCare (Photo: Business Wire)

Leading the round, Vani Kola, Managing Director, Kalaari Capital, “We are delighted to partner with Sumit and Mukesh in their mission to revolutionize chronic disease management. Their experience and deep insights into the market, coupled with their entrepreneurial experience, reinforce our confidence in their ability to disrupt digital health in India. We wish them the very best in their journey.”

Currently 3 Million+ patients and 10k+ doctors and over 1000+ pharmacists use PhableCare’s technology making it the market leader in this segment. The new investment further bolsters PhableCare’s rapid growth in 2021. This funding round marks a 6x jump in PhableCare’s valuation within a short time. The company will use this investment to further strengthen its full-stack and value-driven chronic care ecosystem and accelerate its market expansion, customer acquisition (doctors and patients), brand building, and building new revenue streams.

The start-up has plans to acquire other players through strategic investments, which will consolidate PhableCare’s position in the category. The company has allocated capital and secured additional venture debt to invest in other health-tech startups that can potentially create a thriving healthcare eco-system through capacity and capability expansion.

Speaking on the latest funding, Sumit Sinha, Co-founder, PhableCare, said, “We believe that India needs a focussed chronic care management ecosystem as chronic care has the largest burden on the overall healthcare expenditure. At Phable, we constantly help Chronic Disease Patients to manage their ailment at lower cost and stay out of a hospital for as long as possible. We have demonstrated that this problem can be solved effectively at scale with digital solutions, connected care ecosystem, IOT devices, and data.”

“Our focus over the next 2 years would be to take the technology to 30 Million+ Indian households and 100,000+ super specialist doctors in India and capture 25% of the market. In addition, we will continue to build technology to integrate the healthcare system and players even further,” added Co-founder Mukesh Bansal.

Prior to the current Series B funding led by Kalaari Capital, Phablecare had secured INR 90 crores in Series-A funding led by Manipal Hospitals in March 2021. Later 2021, the start-up received an additional INR 14 cr from Omron Ventures through primary capital infusion and a venture debt facility committed of INR 45 cr from Stride Ventures.

About PhableCare

PhableCare is an app-based and specialized platform for chronic disease care. The innovative disease management app bridges the gap between doctors and patients through a full-stack solution that delivers remote consultations and care, timely and intelligent insights, and simplified access to healthcare essentials.

PhableCare has built an ecosystem of care providers, hospitals, medical device manufacturers, health & wellness product manufacturers, e-Pharmacy retailers, and insurance partners to bring digital healthcare to millions of Indians. Its complete solution for doctors is powered by a decision support system and simplifies patient engagement and clinic management. PhableCare helps doctors extend their practice beyond geographical boundaries and build better relationships with patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005341/en/

CONTACT

Diksha Saini: diksha.saini@ogilvy.com

同じカテゴリーの記事 

  • The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance
  • 免疫機能を高める健康食品「ヘモヒム」が世界的なセンセーションを巻き起こす
  • 增强免疫系统的功能食品Hemohim在全球引起轰动
  • Ochre Bio宣布与Boehringer Ingelheim合作,为晚期肝病患者开发新型再生疗法
  • ルベド・ライフ・サイエンシズ、コスラ・ベンチャーズとアーレン・イノベーション・キャピタル主導の4,000万ドルのシリーズA資金調達を完了